ClinicalTrials.gg
RecruitingNCT07226817Updated Aug 12, 2026

A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants

A Phase 1 interventional study of BMS-986435 in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study is designed to evaluate the relative bioavailability (rBA) of multiple test tablet formulations of BMS-986435 compared to an equal dose of the BMS-986435 reference tablet formulation. The effect of food on the drug levels of selected BMS-986435 tablet formulations will also be evaluated.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria

  • Participants must have a body weight of ≥ 45 kg and between 18 and 32 kg/m2, inclusive
  • Participants must be healthy as determined by medical history, physical examination, vital signs, 12-lead (ECG), clinical laboratory assessments
  • Participants must have documented (LVEF) ≥ 60% and absence of significant cardiac abnormality at screening, as determined by local transthoracic echocardiogram (TTE) assessment
  • Other protocol-defined Inclusion/Exclusion criteria apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Treatment A

    Drug: BMS-986435

  • Experimental
    Treatment B

    Drug: BMS-986435

  • Experimental
    Treatment C

    Drug: BMS-986435

  • Experimental
    Treatment D

    Drug: BMS-986435

  • Experimental
    Treatment E

    Drug: BMS-986435

  • Experimental
    Treatment F

    Drug: BMS-986435

  • Experimental
    Treatment G

    Drug: BMS-986435

  • Experimental
    Treatment H

    Drug: BMS-986435

  • Experimental
    Treatment I

    Drug: BMS-986435

  • Experimental
    Treatment J

    Drug: BMS-986435

  • Experimental
    Treatment K

    Drug: BMS-986435

  • Experimental
    Treatment L

    Drug: BMS-986435

Interventions

  • Specified dose on specified days

    Also known as: MYK-224

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: Up to Day 28

  2. Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))

    Time frame: Up to Day 28

  3. Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

    Time frame: Up to Day 28

Secondary outcomes

  1. Area under the plasma concentration-time curve truncated at 72-hour (AUC(0-72h))

    Time frame: Up to Day 28

  2. Time of maximum observed concentration (Tmax)

    Time frame: Up to Day 28

  3. Half-life (T-HALF)

    Time frame: Up to Day 28

  4. Apparent total body clearance (CLT/F)

    Time frame: Up to Day 28

  5. Volume of distribution of terminal phase (Vz/F)

    Time frame: Up to Day 28

  6. Number of participants with Adverse Events (AEs)

    Time frame: Up to Day 35

  7. Number of participants with Serious AEs (SAEs)

    Time frame: Up to Day 35

  8. Number of participants with clinical laboratory abnormalities

    Time frame: Up to Day 28

  9. Number of participants with vital sign abnormalities

    Time frame: Up to Day 28

  10. Number of participants with physical examination abnormalities

    Time frame: Up to Day 28

  11. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to Day 28

07

Study locations

1 of 1 sites recruiting
  • Quotient Miami
    Miami, Florida 33126, United States
    Recruiting
    • Juliet Vento, Site 0001 · Contact
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2025
First posted
Nov 10, 2025
StartActual
Nov 12, 2025
Primary completionEst.
Dec 17, 2026
CompletionEst.
Dec 17, 2026
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07226817
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Nov 12, 2025
Primary completion
Dec 17, 2026 (estimated)
Completion
Dec 17, 2026 (estimated)
Last update
Aug 12, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delocamten

Start the discussion